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Abstract
Objective: Incomplete recovery from facial palsy has a long-term impact on the quality of life, and medical
options for the sequelae of Bell’s palsy are limited. Invasive treatments and physiotherapy have been employed to
relieve symptoms, but there is limited clinical evidence for their effectiveness. Acupuncture is widely used on Bell’s
palsy patients in East Asia, but there is insufficient evidence for its effectiveness on Bell’s palsy sequelae. The
objective is to evaluate the efficacy and safety of acupuncture in patients with sequelae of Bell’s palsy.
Method/Design: This study consists of a randomized controlled trial with two parallel arms: an acupuncture group
and a waitlist group. The acupuncture group will receive acupuncture treatment three times per week for a total of
24 sessions over 8 weeks. Participants in the waitlist group will not receive any acupuncture treatments during this
8 week period, but they will participate in the evaluations of symptoms at the start of the study, at 5 weeks and at
8 weeks after randomization, at which point the same treatment as the acupuncture group will be provided. The
primary outcome will be analyzed by the change in the Facial Disability Index (FDI) from baseline to week eight.
The secondary outcome measures will include FDI from baseline to week five, House-Brackmann Grade, lip
mobility, and stiffness scales.
Trial registration: Current Controlled-Trials ISRCTN43104115; registration date: 06 July 2010; the date of the first
patient’s randomization: 04 August 2010
Background
Bell’s palsy is an acute, idiopathic, unilateral paralysis of
the face. Its cause is unknown, but mounting evidence
suggests that reactivated herpes viruses from cranial
nerve ganglia play a key role in the development of this
condition; its pattern is consistent with that of periph-
eral neural dysfunction [1,2]. Inflammation of the facial
nerve initially results in reversible neuropraxia and Wal-
lerian degeneration ultimately ensues [1].
The incidence of Bell’s palsy is approximately 30/
100,000 people per year [3]. The prognosis is good, and
approximately 70% of patients recover completely within
6 months without treatment. However, 30% of Bell’s
palsy patients have sequelae, such as residual paresis
(29%), contracture (17%), and facial spasm or synkinesis
(16%) [3]. The incomplete recovery of facial symmetry
can have a long-term impact on the quality of life, such
as difficulty with drinking, eating and speaking, as well
as psychosocial problems [4]. The symmetry of the face
is a determinant of facial charm and influences interper-
sonal attraction [5].
Medical options for the sequelae of Bell’s palsy are
limited to invasive treatments, such as injection of Botu-
linum toxin A and surgical reconstruction. Patients may
be referred to physiotherapists as well, although there is
no evidence favoring one intervention over another
[5-8]. According to a 2009 study, the effect of steroids
on acute Bell’sp a l s yw i t h i n7 2h o u r so ft h eo n s e to f
symptoms is clinically effective, but steroids are not
used on the sequelae of Bell’s palsy [9,10].
Acupuncture is known to be a safe treatment and is
used for a wide range of symptoms associated with
Bell’s palsy [11]. In a 2007 systematic review, the effect
of acupuncture on Bell’sp a l s yw a si n c o n c l u s i v e[ 1 2 ] .
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for Bell’s palsy and various errors in the design of some
of those studies. To overcome such problems, a large-
scale clinical trial investigating the effect of acupuncture
on Bell’s palsy is under way [13]. Here, our aim is to
evaluate the safety and efficacy of acupuncture on the
sequelae of Bell’s palsy.
Method/Design
Objective
The primary objective of this study is to investigate the
efficacy and safety of acupuncture in patients with
sequelae of Bell’s palsy.
Primary outcome
T h ec h a n g ei nt h eF a c i a lD i s a b i l i t yI n d e x( F D I )s o c i a l
[14] score after completing eight weeks of acupuncture
treatment will be compared to the score prior to treat-
ment. This scoring system consists of two domains; phy-
sical score and social score, and has been investigated
for the reliability and validity [14]. FDI-social score eva-
luations will be performed on the first visit, the fifth-
and eighth-week visits. Participants will answer five
multiple choice questions related to problems associated
with facial muscle function during the previous month.
Secondary outcome
Secondary outcome measures will include FDI-social
score from baseline to week five, FDI-physical score,
House-Brackmann (H-B) Grade [15], lip mobility (lip-
length and snout indices) [16], and stiffness scales [17].
The H-B grade has been tested for its reliability [18]
and lip-length and snout indices showed a high correla-
tion with H-B Grade [19]. Stiffness scale is a simple
five-point scale for facial stiffness (1 = no stiffness, 5 =
very stiff) [17].
Unfortunately, there has been no validation study of
Korean version of each of the primary and secondary
outcomes. In our study, two professional translators
made each outcome measurement questionnaire in
Korean, which has been used in our clinical facial palsy
center for evaluating sequelae of facial palsy. So we
decided that these questionnaires are readable and suita-
ble to our study.
Design
A randomized, assessor-blinded, waitlist controlled trial
will be conducted at the Acupuncture and Moxibustion
Department of Kyung Hee University’s Oriental Medical
Hospital in Seoul. (Figure 1) The study includes a
screening period before randomization and a treatment
period of 8 weeks (3 sessions per week). After screening
for inclusion/exclusion criteria, subjects will be rando-
mized to either the acupuncture group or the waitlist
group, in accordance with a computer-generated ran-
dom number list that is hidden until the start of treat-
ment. No-acupuncture waitlist control is used as a
control because sham acupuncture cannot be substi-
tuted for a physiologically inert placebo [20].
Eligibility
Inclusion criteria
To be included, patients have to be diagnosed with
Bell’s palsy at least six months prior to screening.
Patients must score less than 70 on the physical aspect
of the FDI, less than 80 on the social aspect and provide
written informed consent. Participants who are 18 to
65 years old will be recruited using local newspaper
advertisements and posted notices.
Exclusion criteria
Participants will be excluded if they suffer from serious
medical conditions, such as uncontrolled hypertension,
diabetes mellitus requiring insulin injection, past or cur-
rent malignant tumors, severe dyslipidemia, liver or
kidney dysfunction, anemia, active pulmonary tuberculo-
sis or other infectious or systemic diseases that are inap-
propriate for treatment with acupuncture.
Eligible participants will be excluded if they have com-
plicated pathophysiologic conditions of secondary facial
palsy from infection, multiple neuritis, tumors invading
the temporal bone, brain contusion or stroke. Patients
Figure 1 Chronological Flow Chart of the Study Design.
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from the study, as well as those with bilateral or recur-
rent facial palsy. To avoid confounding effects that can
influence patients’ outcome measures, the oral adminis-
tration of steroids or antiviral drugs (acyclovir, valaciclo-
vir, famciclovir, or ganciclovir), a surgical history for
facial palsy, such as facial nerve decompression, recon-
struction of the facial nerve or muscle, and history of
acupuncture, moxibustion, vesiculation and massage
therapy within three months will also result in exclusion
from the study. With regard to safety and compliance
issues, patients with other neurological illnesses, neurop-
sychiatric diseases, present or planned pregnancy, cur-
rent lactation, or scars on the treatment area will also
be excluded.
Over-the-counter (OTC) drugs for common colds,
dyspepsia, headaches, etc. will be allowed. However
OTC drugs of unknown components or indicated for
Bell’s palsy related symptoms will not be allowed. All
patients will be instructed to disclose all medication use
prior to enrollment. Records on the drugs taken by
each patient will be obtained at every visit, and patients
will be requested to inform us of any change to their
medication or supplement regimen. Additional acu-
puncture treatments, herbal medicines, or medical inter-
ventions elsewhere will not be allowed throughout the
study.
Acupuncture treatment protocol
Acupuncture intervention
Acupuncture will be performed by specialists in oriental
medicine. Participants will be randomly assigned to the
acupuncture treatment group or the waitlist group. The
acupuncture group will receive acupuncture treatments
3 times/week for a total of 24 sessions over 8 weeks, fol-
lowing the details of the STandards for Reporting Inter-
ventions in Clinical Trials of Acupuncture (STRICTA)
2010 checklist as shown in Table 1. In the acupuncture
treatment group, 18 acupuncture points [22] (ST4, ST6
on the unaffected side, ST1, EX-HN4, TE23, LI20 on
the affected side, TE17, ST9, LI10, LI4, ST36 and GB34
on both sides) will be used. These selected acupuncture
points were based on acupuncture specialist forums and
the textbook of acupuncture in Korea [23].
A 0.20-mm (diameter) × 30-mm (length) disposal nee-
dle (Dongbang Acupuncture Inc, Boryeong, Korea)
(Table 1) will be inserted into each acupuncture point
to a depth of 5-30 mm, depending on the points
selected. All participating acupuncture doctors will use
de-qi sensation techniques to manually manipulate and
maintain the needles for a 10-minute period with
manipulation at the start and end of the 10-minute per-
iod. Additional interventions, i.e., infrared irradiation or
electronic stimulation, will not be allowed during the
acupuncture treatment. The ST4 and ST6 needles will
penetrate to a depth of 20 to 30 mm using an oblique
angle of insertion toward each other’s tips. The ST1 and
EX-HN4 needles will penetrate to a depth of 5 to
10 mm at an oblique angle toward the eye, using cau-
tion so as not to damage the conjunctiva when applying
the ST1 needle. The TE23 needle will penetrate to a
depth of 20 to 30 mm at an oblique angle toward the
ear. The LI20 needle will be inserted to a depth of 20 to
30 mm at an oblique angle toward the root of the nose.
The TE17, ST9, LI10, LI4, ST36 and GB34, needles will
be inserted perpendicular to the skin to a depth of 20 to
30 mm. (Table 2) These manipulations will be repeated
after 10 minutes. Needling will be carried out with parti-
cipants in the supine position, and needle sites will be
swabbed with 2% boric acid before insertion. Upon
withdrawal of the needle, dry sterilized cotton balls will
be firmly applied to the insertion points.
Outcome measures
After screening, the participants will answer the FDI
questionnaire three more times: at the first visit, at five
weeks, and at eight weeks after the final treatment. The
assessment of H-B Grade, lip mobility, and stiffness will
be conducted at each time point.
The expectations of the participants will be recorded
using the credibility and expectancy questionnaire [24]
to determine whether expectations affected outcomes.
Any adverse events as a result of acupuncture will be
monitored and recorded. At the end of the trial, the par-
ticipants in the acupuncture group will be asked if they
are satisfied with the outcome.
Because the knowledge of the group assignment could
modify outcome assessment, we will ensure that the
independent assessor is blinded.
Statistical methods
Analysis
Analysis will be performed for an intention-to-treat popu-
lation consisting of all randomized participants regardless
of their actual treatment received. Any missing data will
be replaced with ones by a multiple imputation technique
[25]. All data will be analyzed descriptively. Of the primary
and secondary outcome measurements, variables of FDI,
H-B grade and stiffness scale are discrete ordinal variables
whereas lip mobility is recorded as a continuous variable.
For primary and secondary outcome measurements, the
mean differences from the baseline values to the end of
treatment will be compared between the two groups using
the two-sample t-test if the data are distributed normally.
In case of non-normally distributed data, Wilcoxon rank-
sum test will be performed. If baseline values of outcome
measurements are significantly different between groups,
analysis of co-variance (ANCOVA) will be performed
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group as fixed factor.
All adverse events reported during the study will be
included in the clinical report, and the prevalence of
adverse events will then be calculated. The percentage
of subjects with adverse events in each group will be
calculated and compared using the chi-squared test or
Fisher’s exact test.
Statistical analyses will be performed using the SAS
statistical package program (ver. 9.1.3), and the level of
significance will be established at a = 0.05.
Sample size
Sample size was calculated from the result of a mime
therapy trial conducted on patients with sequelae of
Bell’s palsy of which design was randomized parallel wait-
list controlled trial [17]. We assumed that the effect size
of our invasive acupuncture therapy will be at least equal
to this non-invasive mime therapy. Also we decided the
a l l o c a t i o nr a t i ot ob e2 : 1w i th the consideration that
fewer patients should be allocated to the waitlist group.
In the mime trial, the mean difference of follow-up
FDI-social score between groups was 14.5 and pooled
standard deviation was 14.5 within each group [17]. The
alpha value and power were 0.05 and 0.8 respectively.
F r o mt h e s ev a l u e sw ec a l c u l a t e ds a m p l es i z ef o ri n d e -
pendent two sample t-test (one-tailed) that is 26 for
acupuncture group and 13 for waitlist group with con-
sideration of 20% drop-out. And this assumed mean dif-
ference of FDI-social score between groups is
considered to be sufficiently important in an expert dis-
cussion consisting of clinicians who work in Bell’sp a l s y
clinics for more than 10 years.
Data handling
Investigators will enter the information required by the
protocol into the case report forms. Unclear entries and
omissions will be entered on data query forms, which
will be returned to the investigational site for resolution.
The data will be summarized according to demographic
baseline characteristics, effectiveness and safety
observations.
Table 1 Details of the proposed acupuncture intervention according to the STRICTA 2010 Checklist
Acupuncture
rationale
Style of acupuncture Traditional Korean Medicine
Rationale for treatment Acupuncture has been historically used to treat facial palsy. Additionally, it is
known to be a safe treatment used in a wide range of symptoms caused by
Bell’s palsy [11].
Extent to which treatment varied The subjects of the acupuncture group all receive the same treatment
Details of needling Number of needle insertions per subject
per session
18
Names of the insertion points (uni/
bilateral)
ST4, ST6, (unilateral, unaffected side) ST1, EX-HN4, TE23, LI20 (unilateral, affected
side) TE17, ST9, LI10, LI4, ST36 and GB34 (bilateral)
Depth of insertion 5-30 mm (exact depth shown in Table 2)
Response sought De-qi
Needle stimulation Manual
Needle retention time 10 minutes
Needle type 0.20 mm (diameter) × 30 mm (length) disposal needle (Dongbang Acupuncture
Inc, Boryeong, Korea)
Treatment regimen Number of treatment sessions 24
Frequency and duration of treatment
sessions
3 sessions/week for 8 weeks
Other components
of treatment
Details of other interventions administered
to the acupuncture group
No other interventions are done
Setting and context of treatment All subjects are informed that they will receive acupuncture treatment, which
can potentially reduce the sequelae of Bell’s palsy symptoms; however, the
control group would have to complete the three evaluations during the first 8
weeks before receiving the same treatment as the acupuncture group.
Practitioner
background
Description of participating acupuncturists Specialists in Oriental Medicine with at least 3 years of practice in acupuncture
Control or
comparator
interventions
Rationale for the control or comparator in
the context of the research question
No-acupuncture waitlist control is used as a control because sham acupuncture
cannot be a substituted for a physiologically inert placebo [20]
Precise description of the control or
comparator
The control group forms a waitlist and completes the evaluations during the
first 8 weeks after randomization before receiving the same treatment as the
acupuncture group.
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Regular monitoring will be conducted at the investiga-
tional site for quality control. Additionally, investigators
convene to discuss practical issues that may be encoun-
tered, such as adjusting recruitment capacity, dealing
with serious adverse events, revising the protocol, and
other important issues that may be raised by investiga-
tors and participants. The assessment of safety will pri-
marily be based on the frequency of adverse events,
which will include all serious adverse events. Informa-
tion regarding adverse events will be summarized by
presenting the number and percentage of the partici-
pants who experienced them. The data will also be cate-
gorized according to the affected body region. All of the
other information collected (e.g., severity or relation to
acupuncture treatments) will be listed appropriately.
Randomization and allocation
Computerized randomization will be performed by an
outside researcher who will not be in direct contact
with the participants. The assessor will be blinded to the
group allocation. The investigator performing the acu-
puncture intervention cannot be intrinsically blinded,
but will not be allowed to communicate with the partici-
pants or the assessor about the treatment procedures
and outcomes. A sealed envelope containing allocation
sequence number for each patient will be opened right
after each patient meets eligibility criteria and informed
consent is made. If any error or disclosure with regard
to randomization occurs, a new randomization sequence
will be generated starting from the problematic serial
number and applied to the patients from then on.
Ultimately, 39 participants will be enrolled in the
study.
A balanced block randomization will be used to assign
26 participants to the acupuncture group and 13 to the
waitlist group; the exact block size will be concealed
from any personnel who will be in direct contact with
patients. Following the baseline assessment, eligible par-
ticipants will be assigned to one of two groups: a group
receiving acupuncture or a control waitlist group. All
subjects will be informed that there is a possibility they
will be allocated to the waitlist control group and in
that case, they should wait 8 weeks before receiving acu-
puncture treatments during 8 weeks. To eliminate
observation bias, the independent assessor will be
blinded prior to the analysis of the data.
Ethics
Written informed consent will be obtained from each
participant. This study is approved by the Institutional
Review Board of Kyung Hee University’s Oriental Medi-
cal Hospital.
Abbreviations
ANCOVA: analysis of co-variance (ANCOVA); FDI: Facial Disability Index; H-B:
House-Brackmann.
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Table 2 Acupuncture Points and Needling Procedure
Acupuncture Point Direction Depth (mm)
ST4 (unaffected side) Transversely, toward ST6 20-30
ST6 (unaffected side) Transversely, toward ST4 20-30
ST1 (affected side) Transversely, toward the eye 5-10
EX-HN4 (affected side) Transversely, toward the eye 5-10
TE23 (affected side) Transversely, toward the ear 20-30
LI20 (affected side) Obliquely along nasolabial sulcus toward the root of nose 20-30
TE17 (both sides) Perpendicular to the skin 20-30
ST9 (both sides) Perpendicular to the skin 20-30
LI10 (both sides) Perpendicular to the skin 20-30
LI4 (both sides) Perpendicular to the skin 20-30
ST36 (both sides) Perpendicular to the skin 20-30
GB34 (both sides) Perpendicular to the skin 20-30
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